Why is the search for pre-eclampsia prevention so elusive?
BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3536 (Published 12 September 2018) Cite this as: BMJ 2018;362:k3536- Jenny E Myers, clinical senior lecturer1,
- Marcus Green, chief executive2,
- Lucy C Chappell, NIHR research professor in obstetrics3
- 1University of Manchester, UK
- 2Action on Pre-eclampsia, UK
- 3School of Life Course Sciences, King’s College London, UK
- Correspondence to: LC Chappell lucy.chappell{at}kcl.ac.uk
Pre-eclampsia remains a leading cause of maternal and perinatal mortality and morbidity globally. A recent World Health Organization analysis estimated that hypertensive disorders of pregnancy account for 14% of maternal deaths worldwide.1 These stark facts drive the search for effective, safe, and affordable treatment to prevent pre-eclampsia. Although low dose aspirin reduces the risk of pre-eclampsia by 17%,2 the remaining burden of disease is considerable and additional prophylactic treatments are still needed.
In a linked paper, Wen and colleagues (doi:10.1136/bmj.k3478) report the results of FACT, a double blinded, multinational randomised controlled trial that aimed to determine whether daily supplementation with 4 mg folic acid from the first trimester reduced pre-eclampsia in women with risk factors for the condition.3 Pre-eclampsia occurred in a similar proportion in the placebo and intervention groups and the authors concluded that high dose folic acid does not prevent pre-eclampsia in high risk women. All secondary outcomes (including proportions of small for gestational …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.